The Mode of Action of CY216 and CY222 in Plasma

Summary

Three fractions of the low molecular weight heparin CY216 (fraxiparin, mean molecular weight [MMW] 5,090), with MMWs of respectively, 3,090, 4,400 and 7,910 were prepared by gel permeation chromatography. From CY222 (MMW 3,770) as well as from CY216 and its three fractions the material with high affinity to antithrombin III (AT III) was obtained by chromatography on immobilised AT III. The molecular weight distribution of each of the ten preparations thus obtained was determined by high performance liquid chromatography, while the content of AT III binding material was determined by stoichiometric titration of AT III, monitored by intrinsic fluorescence enhancement.

We measured the effect of all heparins on the decay of endogenous thrombin in plasma and on the overall generation of thrombin in plasma, triggered via the extrinsic or via the intrinsic pathway. From these data we calculated the time course of prothrombin conversion, i. e. the course of factor Xa activity as expressed by prothrombinase activity.

It was found that in platelet-poor plasma the anticoagulant properties of the heparins are largely dependent on their antithrombin action, which is determined by their content of high affinity material with a MW of 5,400 or higher. The specific antithrombin activity of all heparins, when expressed in terms of material with high affinity to antithrombin III (HAM) with a MW >5,400 is 13.0 min^-1/(μg/ml) (range 10.5-15.9). The anticoagulant potency is not influenced by the presence of low-affinity material and hardly by material with MW <5,400.

In platelet-rich plasma, however, the presence of non-AT III binding material enhances the inhibition, presumably by neutralising heparin binding material originating from activated platelets. The ultra low MW fractions (<3,400) show a similar activity in PPP and in PRP.

• References

• 1 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis. Verstraete M, Vermylen M, Lijnen J, Arnout HR. (eds). Int Soc Thromb Haemostas and Leuven University Press; Leuven: 1987. pp 17-36
• 2 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 3 Pieters J, Lindhout T, Hemker HC. In situ generated thrombin is the only enzyme that effectively activates factor VIII and factor V in plasma. Blood 1989; 74: 1021-1024
• 4 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma its inhibition by heparin. Thromb Haemostas 1989; 61: 25-29
• 5 Choay J, Petitou M, Lormeau JC, Synaï P, Casu B, Gatti G. Structure activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499
• 6 Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemostas 1989; >61 (03) 379-401
• 7 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for Antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; >47 (03) 244-248
• 8 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RAF, Hemker HC. The role of phospholipid and factor Va in the prothrombinase complex. J Biol Chem 1980; 249: 7798-7807
• 9 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 10 Owren P, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-218
• 11 Nordeman B, Bjôrk I. Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies. Biochemistry 1987; 17: 3339-3344
• 12 Smith RL. Titration of activated bovine factor X. J Biol Chem 1973; 248: 2418-2423
• 13 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 14 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-460
• 15 Thunberg L, Lindahl U. On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J 1979; 181: 241-243
• 16 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sôden-strôm G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
• 17 Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindhal U, Thomas DP. Anticoagulant activities of heparin oligosaccharides. Thromb Res 1984; 34: 125-133
• 18 Hoylaerts M, Owen WG, Collen D. Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. J Biol Chem 1984; 259: 5670-5677
• 19 Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem J 1986; 238: 329-333
• 20 Danielson A, Raub E, Lindahl U, Bjôrk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-15473
• 21 Jesty J. Analysis of the generation and inhibition of activated coagulation factor X in pure systems and in human plasma. J Biol Chem 1986; 261: 8695-8702
• 22 Jesty J. The kinetics of inhibition of a-thrombin in human plasma. J Biol Chem 1986; 261: 10313-10318
• 23 Barrowcliffe TW, Shirley-Le Y. The effect of calcium chloride on antiXa activity of heparin and its molecular weight fractions. Thromb Haemostas 1989; >62 (03) 950-954
• 24 O’Neall-Speight M, Griffith MJ. Calcium inhibits the heparin-catalyzed antithrombin III/thrombin reaction by decreasing the apparent binding affinity of heparin for thrombin. Arch Biochem Biophys 1983; 225 (02) 958-963
• 25 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-588
• 26 Béguin S, Dol F, Hemker HC. Secondary effect of antithrombin property of unfractionated heparin: Factor IXa inhibition in the intrinsic pathway. Br J Haematol 1990; 76 (Suppl) (01) 24
• 27 Béguin S, Dol F, Hemker HC. Factor IXa inhibition contributes to the heparin effect. Thromb Haemostas 1991; 66: 306-309
• 28 Hemker HC, Esnouf MP, Hemker PW, Swart ACW, Macfarlane RG. Formation of prothrombin converting activity. Nature 1968; 215: 246-251
• 29 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 30 Lindhout T, Govers-Riemslag JWP, Waart-van-de P, Hemker HC, Rosing J. Factor Va-Factor Xa interaction. Effects of phospholipid vesicles of varying composition. Biochemistry 1982; 21: 5494-5502
• 31 Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring inhibitor to activated factor X. J Biol Chem 1971; 246: 3703-3711
• 32 Ofosu FA, Smith LM, Anvari N, Blajchman MA. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Thromb Haemostas 1988; 60: 193-198
• 33 Béguin S, Mardiguian J, Lindhout T, Hemker HC. The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma. Thromb Haemostas 1989; 61: 30-34
• 34 Walenga JM, Bara L, Petitou M, Fareed J, Samama M, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33
• 35 Loscalzo J, Melnick B, Handin RI. The interaction of platelet four and glycosaminoglycans. Arch Biochem Biophys 1985; 240: 446-455
• 36 Walz DA, Hung GL. In vivo studies on the binding of heparin and its fraction with platelet factor 4. Semin Thromb Hemostas 1984; 11 (01) 40-47